Format

Send to

Choose Destination
Sci Transl Med. 2011 Mar 23;3(75):75cm9. doi: 10.1126/scitranslmed.3001712.

Accrual to cancer clinical trials in the era of molecular medicine.

Author information

1
Section of Hematology-Oncology and Comprehensive Cancer Center, University of Chicago, Chicago, IL 60637, USA. rschilsk@medicine.bsd.uchicago.edu

Abstract

Enrollment of patients in a clinical trial is difficult as a result of a host of well-documented barriers. In the field of oncology, molecularly targeted treatments have demonstrated considerable therapeutic promise. At the same time, clinical testing of these targeted agents has introduced new complexities in the decision-making process by patients or providers on whether to participate in clinical trials. Explored in this Commentary are challenges of and potential solutions for the clinical testing of modern cancer therapies.

PMID:
21430267
DOI:
10.1126/scitranslmed.3001712
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center